the application of automatic instruments for the measurement of blood pressure in controlled clinical trials may be derived.
(1) Substitution of the standard Korotkoff method by automatic devices in clinical trials must be well-founded. The principle of automated measurement-Korotkoff sounds, oscillometry, ultrasound and othersmakes no difference.
(2) The applied instruments must be tested before starting the trial, followed by continuous surveillance of all instruments used during the trial.
(3) When testing the automatic devices, the relevant characteristics of the patients included in the trial, such as their age 6-8 and range of blood pressure, 9 must be representative. (4) The consequences of the test results for the conclusions of the clinical trial must be discussed in its final publication. This point is extremely important when looking for new target values for antihypertensive treatment, but also relevant in comparative drug studies.
Up to now, the non-automated
Reply to the letter from M Anlauf, U Tholl, H Hirche and F Weber
We are surprised that Prof Anlauf and colleagues 1 have commented on the blood pressure measurement method in the HOT Study 2 such a long time after the results of the study were published. We find it even more astonishing, as their comments are mainly irrelevant.
We used the average of four readings for the comparison between the methods. This is closer to the clinical situation than a single reading. In comparison with the situation in the HOT Study 2 where three readings were routinely used our results indicate good agreement between the methods. These results are in line with the BHS 3 criteria except for difference in systolic blood pressmethod of indirect blood pressure measurement as developed by Riva-Rocci and Korotkoff remains the golden standard which yielded nearly all insights into the problem of hypertension and its management. At this time, a new standard of automated blood pressure measurement has not been created, so we can make use of the indisputable advantages of automation without risk only by sticking to well defined protocols for continuous comparisons. ) and not vs eg the value from the sphygmomanometer, is to avoid a spurious correlation that otherwise would emerge due to the measurement error in the xvariable. Although this method normally gives satisfactory unbiased result it can give a small spurious correlation when the two methods have different measurement errors. 5 In the case with diastolic blood pressure the Visomat method have slightly higher intra-individual variation and this is probably the cause for the weak relation between difference and average value.
M Anlauf
Anlauf et al 1 notes that for every third subject a diastolic blood pressure of 82 mm Hg with the Visomat device may correspond to ±5 mm Hg taken by the Korotkoff method. Although this seems like a large deviation the BHS criteria (grade A or B) permit that up to 50% of the subjects have deviations that are as large as 5 mm Hg. As Prof Anlauf et al are referring to the BHS criteria a number of times in their letter we find it surprising that they do not note that this deviation is well within the criteria.
It is important to realise that the variation observed in a difference between two methods is the sum of the measurement errors of each method. The BHS criteria take account of this effect. Although sphygmomanometry is considered a gold standard for measurement of blood pressure it contains an intra-individual variation (eg, 4.1% coefficient of variation for diastolic blood pressure) that canJournal of Human Hypertension not be neglected. In this context it is important that the total measurement error in the difference is not heavily dependent of one the methods. We have been able to show (due to the design with repeated measurements with each method) that the two methods have largely similar intra-individual variations.
In conclusion our results show that the two methods agree well (especially for the target variable diastolic blood pressure). The weak relation between difference and average value lacks clinical significance (particularly in the important diastolic range 80-100 mm Hg). The number of subjects falling within 5-mm Hg difference is well within the BHS limits. As sphygmomanometry, in clinical use in a multi-centre setting as the HOT Study, also would introduce an inter-observer variation (that could not be estimated from our study) we are confident that the choice of methods was correct in the HOT Study.
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